Skip to main content
. 2015 Nov 20;310(2):L202–L211. doi: 10.1152/ajplung.00151.2015

Fig. 5.

Fig. 5.

Effect of a TLR3 antagonist on poly(I:C)-induced CCL5 (A) and IL-8 (B) expression. Fetal ASMs were pretreated with a TLR3 antagonist, N-[(3-chloro-6-fluorobenzo[b]thien-2-yl)carbonyl]-d-phenylalanine (CU CPT 4a), for 1 h and subsequently treated with media only (control) or poly(I:C) for 24 h. Pretreatment with TLR3 antagonist significantly decreased CCL5 (A) and IL-8 (B) secretion induced by poly(I:C). Values are means ± SE; n = 4 samples. *Significant difference from control, P < 0.05. †Significant difference between poly(I:C) and TLR3 antagonist + poly(I:C) treatments, P < 0.05.